glp 1 is it safe for weight loss GLP-1 vs Ozempic — What's the Difference? The Benefits of GLP-1 Therapy:

The placebo-corrected increase in mean HR from baseline at the end of the study (day 39) was up to 3 and 68 bpm for the 30- and 50-mg dose, respectively

Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)

10.1001/jama.2023.24945

Nausea occurs in 15-40% of patients initiating GLP-1 agonists, with vomiting, diarrhea, and abdominal discomfort also common, particularly during dose escalation

Pharmacology, physiology, and mechanisms of incretin hormone action

Most importantly, do not discontinue your medication without medical guidance, as symptoms often improve with continued use and appropriate management strategies